Betterlife Pharma Inc Stock Price, News & Analysis

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced that its collaborators from Carleton University will present findings on BETR-001, a non-hallucinogenic LSD derivative, at the SOBP Conference, April 27-29, 2023, in San Diego. Preclinical data indicate that BETR-001 enhances stress-coping behaviors and reverses anxiety and depression in mouse models, correlating with increased neuroplasticity in the prefrontal cortex. Driven by the serotonin 5-HT2A receptor, these effects position BETR-001 as a promising candidate for treating mood disorders without the regulatory challenges of traditional psychedelics. CEO Ahmad Doroudian noted that ongoing IND-enabling studies will pave the way for human trials. BetterLife's proprietary patents protect BETR-001, facilitating potential self-administration and broader patient access.

BetterLife Pharma Inc., a biotechnology company focused on mental disorder treatments, announced that its CEO Dr. Ahmad Doroudian and COO Dr. Hooshmand Sheshbaradaran will present at the Bloom Burton Healthcare Investor Conference on April 26, 2023, in Toronto.

This prominent event invites leading public and promising private companies in the healthcare sector to connect with global investors. Attendees can expect presentations and one-on-one meetings.

BetterLife is advancing two compounds, BETR-001 and BETR-002, targeting neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic LSD derivative, while BETR-002 is based on honokiol from magnolia bark.

For registration details, visit the Bloom Burton website.

BetterLife Pharma Inc. has announced the publication of an article on its lead candidate BETR-001 (2-bromo-LSD), highlighting its potential for treating depression without hallucinations. The article, featured in Drug Discovery & Development, elaborates on BETR-001's positive preclinical data and safety profile compared to LSD, developed in partnership with notable scientists. The company is advancing BETR-001 towards human clinical trials post-IND-enabling studies. BetterLife also develops other compounds for neuro-psychiatric and neurological disorders, including BETR-002. The management emphasizes the significant therapeutic potential of BETR-001 in neuro-psychiatric conditions.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced on March 22, 2023, that Medical Xpress published an article discussing its lead candidate, BETR-001 (2-bromo-LSD), aimed at treating mood disorders. The article describes the positive data from the pharmacological characterization of BETR-001, conducted with renowned scientists. CEO Ahmad Doroudian highlighted BETR-001's therapeutic potential and improved safety profile compared to LSD, with human clinical trials projected to commence after IND-enabling studies. BetterLife is focused on developing innovative treatments for neuro-psychiatric disorders, including BETR-002, based on honokiol.

BetterLife Pharma Inc. has announced the publication of a study on its lead candidate, BETR-001 (2-bromo-LSD), in the journal Cell Reports. The study demonstrates that BETR-001 has distinct pharmacological advantages over LSD, including non-hallucinogenic effects and a safer cardiovascular profile. BETR-001 showed partial agonism at the 5-HT2A receptor while lacking 5-HT2B agonism. Additionally, it induced neuroplasticity and promoted coping behavior in animal models of depression and anxiety. BetterLife aims to begin human clinical trials for BETR-001 by the end of 2023, indicating potential therapeutic applications for mood disorders.

BetterLife Pharma Inc. has engaged Bloom Burton Securities for strategic advisory services aimed at supporting its growth and clinical trial efforts. The company has made notable progress in developing BETR-001, a non-hallucinogenic LSD derivative, which is currently undergoing preclinical studies and manufacturing preparations. BetterLife also highlighted its achievements in advancing therapies for mental health disorders and viral infections. Regulatory studies and patent applications are underway to bolster the company's intellectual property portfolio. This collaboration is expected to enhance its financing capabilities as it progresses toward clinical trials.